首页> 外文期刊>The Canadian journal of cardiology >Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter.
【24h】

Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter.

机译:加拿大心血管协会2010年心房纤颤指南:心房纤颤/房扑的导管消融术。

获取原文
获取原文并翻译 | 示例
           

摘要

Catheter ablation of atrial fibrillation (AF) offers a promising treatment for the maintenance of sinus rhythm in patients for whom a rhythm control strategy is desired. While the precise mechanisms of AF are incompletely understood, there is substantial evidence that in many cases (particularly for paroxysmal AF), ectopic activity most commonly located in and around the pulmonary veins of the left atrium plays a central role in triggering and/or maintaining arrhythmic episodes. Catheter ablation involves electrically disconnecting the pulmonary veins from the rest of the left atrium to prevent AF from being triggered. Further substrate modification may be required in patients with more persistent AF. Successful ablation of AF has never been shown to alter mortality or obviate the need for oral anticoagulation; thus, the primary indication for this procedure should be improvement of symptoms caused by AF. The success rate of catheter ablation for AF is superior to the efficacy of antiarrhythmic drugs, but success is still in the range of 75%-90% after 2 procedures. Ablation is also associated with a complication rate of 2%-3%. Thus, ablation should primarily be used as a second-line therapy after failure of antiarrhythmic drugs. In contrast to AF, catheter ablation of atrial flutter has a higher success rate with a smaller incidence of complications. Thus, catheter ablation for atrial flutter may be considered a first-line alternative to antiarrhythmic drugs.
机译:导管房颤消融术为维持节律的患者提供了一种有希望的治疗方法,以维持其节律控制策略。尽管房颤的确切机制尚不完全清楚,但有大量证据表明,在许多情况下(尤其是阵发性房颤),异位活动最常位于左心房肺静脉内和周围,在触发和/或维持中起着核心作用。心律失常发作。导管消融包括将肺静脉与左心房的其余部分断开,以防止房颤被触发。持续性房颤患者可能需要进一步的基质修饰。房颤的成功消融从未显示出能够改变死亡率或消除口服抗凝治疗的必要性。因此,该手术的主要指征应该是改善由房颤引起的症状。 AF导管消融的成功率优于抗心律失常药物的疗效,但经过2个步骤的成功率仍在75%-90%的范围内。消融还与2%-3%的并发症发生率相关。因此,消融应主要用作抗心律不齐药物失败后的二线治疗。与房颤相比,房扑的导管消融成功率更高,并发症发生率也更低。因此,用于房扑的导管消融可被视为抗心律不齐药物的一线替代药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号